Vergori, Alessandra;
Lepri, Alessandro Cozzi;
Cicalini, Stefania;
Matusali, Giulia;
Bordoni, Veronica;
Lanini, Simone;
Meschi, Silvia;
... Antinori, Andrea; + view all
(2022)
Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV.
Nature Communications
, 13
, Article 4922. 10.1038/s41467-022-32263-7.
Preview |
PDF
Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV.pdf - Other Download (1MB) | Preview |
Abstract
In order to investigate safety and immunogenicity of SARS-CoV-2 vaccine third dose in people living with HIV (PLWH), we analyze anti-RBD, microneutralization assay and IFN-γ production in 216 PLWH on ART with advanced disease (CD4 count <200 cell/mm3 and/or previous AIDS) receiving the third dose of a mRNA vaccine (BNT162b2 or mRNA-1273) after a median of 142 days from the second dose. Median age is 54 years, median CD4 nadir 45 cell/mm3 (20-122), 93% HIV-RNA < 50 c/mL. In 68% of PLWH at least one side-effect, generally mild, is recorded. Humoral response after the third dose was strong and higher than that achieved with the second dose (>2 log2 difference), especially when a heterologous combination with mRNA-1273 as third shot is used. In contrast, cell-mediated immunity remain stable. Our data support usefulness of third dose in PLWH currently receiving suppressive ART who presented with severe immune dysregulation.
| Type: | Article |
|---|---|
| Title: | Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1038/s41467-022-32263-7 |
| Publisher version: | https://doi.org/10.1038/s41467-022-32263-7 |
| Language: | English |
| Additional information: | This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| Keywords: | Science & Technology, Multidisciplinary Sciences, Science & Technology - Other Topics, ANTIRETROVIRAL THERAPY, SARS-COV-2, INFECTION, SAFETY, INFLAMMATION, INDUCTION, COHORT |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health > Infection and Population Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10155371 |
Archive Staff Only
 |
View Item |
